All In Biotech

Drug Trial Radar · NCT07937462

The Efficacy and Safety of DLBS1442 in Patients With Primary Dysmenorrhea

A Randomized, Double-Blind, Parallel, Placebo Controlled, Dose-Ranging Study to Evaluate The Efficacy and Safety of DLBS1442 in Patients With Primary Dysmenorrhea

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

210

Planned (sponsor's estimate)

Start

Aug 1, 2026

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Dexa Medica GroupIndustry
Sponsor type
Industry
Collaborators
PT Equilab International
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate whether DLBS1442 can alleviate primary dysmenorrhea in young adults aged 18 to 21 years. The main question it aims to answer is: 1\. Does DLBS1442, at doses of 100 mg and 200 mg, reduce dysmenorrhea pain compared with placebo, as measured by the change from baseline in Visual Analogue Scale (VAS) pain score at predefined time points after the first dose? Researchers will compare DLBS1442 100 mg, DLBS1442 200 mg, with placebo to determine whether DLBS1442 is more effective in reducing dysmenorrhea pain. Participants will: 1. Take DLBS1442 or placebo three times daily for up to 5 consecutive days during one menstrual cycle. Treatment may be discontinued earlier if pain completely resolves (VAS = 0). 2. Return to the study site on Day 6 after Visit 1 for assessment of study drug compliance, diary review, return of unused study medication and packaging, and study-related evaluations. 3. Record the Visual Analogue Scale (VAS) pain score before each study drug administration. 4. Complete the quality-of-life questionnaire on Days 1, 2, 3, and 6. 5. Record any adverse events and concomitant medications used throughout the study. 6. Record the use of rescue medication (paracetamol), including the VAS pain score immediately before each rescue medication dose.

Conditions

  • Primary Dysmenorrhea

Interventions

  • DLBS1442Drug

    DLBS1442 is supplied as 100 mg oral capsules. Participants will receive either : 1. DLBS1442 100 mg + Placebo; or 2. DLBS1442 100 mg + DLBS1442 100 mg three times daily for up to 5 consecutive days during one menstrual cycle, according to the randomized treatment assignment. Treatment may be discontinued once complete pain relief is achieved (Visual Analogue Scale \[VAS\] = 0).

  • PlaceboDrug

    Matching placebo capsules identical in appearance to DLBS1442 capsules. Participants will receive either one placebo capsule together with one DLBS1442 100 mg capsule or two placebo capsules three times daily for up to 5 consecutive days during one menstrual cycle, according to the randomized treatment assignment. Treatment may be discontinued once complete pain relief is achieved (Visual Analogue Scale \[VAS\] = 0).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Visual Analogue Scale (VAS) Pain Score Within 6 Hours After the First DoseTime frame: Baseline to 6 hours after the first dose.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Klinik Pratama Equilab International

    Jakarta, Jakarta Special Capital Region, Indonesia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.